Authors
Ajay K. Gopal, MD, FACP, is the medical director for Hematology, Malignancies/Hematology, the clinical research director for the Lymphoma Program and an professor in the Clinical Research Division at Fred Hutch Cancer Center; professor of Hematology and Oncology in the Division of Hematology and Oncology at the University of Washington School of Medicine, and the Stephen Hans Petersdorf, MD, Endowed Chair in Cancer Care at the University of Washington Medicine, both located in Washington.
Advertisement
Advertisement
Trending on OncLive
1
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
Orca-T With Reduced-Intensity Conditioning Yields Robust Efficacy in Hematologic Malignancies
4
TRX103 Tr1 Cell Therapy Shows Manageable Safety and Dose-Dependent Kinetics After HLA-Mismatched HCT in Hematologic Malignancies
5


